<DOC>
	<DOCNO>NCT00002835</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness two regimen combination chemotherapy treat patient intermediate-grade immunoblastic lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy early intensification v alternate triple chemotherapy patient intermediate-grade immunoblastic lymphoma poor prognostic feature . - Compare , prospective manner , cost/benefit ratio regimens patient . - Determine value monitor minimal residual disease detection via vitro culture method polymerase chain reaction analysis peripheral stem cell apheresis product longitudinal monitoring blood bone marrow sample patient treat regimen . OUTLINE : This randomize study . Patients stratify accord tumor score ( 3 4 v 5 6 ) . During first course induction , patient receive IDSHAP comprise idarubicin ( IDA ) cisplatin IV continuously day 1-4 , cytarabine ( ARA-C ) IV 2 hour day 5 , methylprednisolone ( MePRDL ) IV 15 minute day 1-5 . During second course induction , patient receive MBIDCOS comprise vincristine , bleomycin , cyclophosphamide IV 15 minute day 1 , IDA IV continuously MePRDL IV 15 minute day 1-3 , methotrexate ( MTX ) IV 2 hour day 10 , oral leucovorin calcium every 6 hour day 11 12 . Each course last 3 week absence disease progression unacceptable toxicity . Patients stable respond disease induction randomize 1 2 treatment arm . Arm I - Patients receive follow 3 course early intensification . - First course : Patients receive ifosfamide ( IFF ) IV continuously etoposide ( VP-16 ) IV 2 hour every 12 hour day 1-3 . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) begin day 5 continue blood count recover autologous peripheral blood stem cell ( PBSC ) harvest , select CD34 positive cell , purge vitro . If 5 % WBC contain lymphoma cell induction , 2 course IFF VP-16 administer PBSC harvest . - Second course : Patients receive IFF IV continuously day 1-3 , mitoxantrone ( DHAD ) IV day 1 , G-CSF SC first course . - Third course : Patients receive carmustine IV 1 hour day -6 , ARA-C VP-16 IV every 12 hour day -5 -2 , melphalan IV day -1 . PBSC reinfused day 0 . G-CSF administer SC begin day 0 continue blood count recover . Each course last 3 week absence disease progression unacceptable toxicity . Arm II - Patients receive IDSHAP course 2 5 , MBIDCOS course 3 6 , IFF VP-16 IV 1 hour day 1-3 DHAD IV 15 minute day 1 course 1 , 4 , 7 . Each course last 4 week absence disease progression unacceptable toxicity . Patients residual disease completion arm I II treatment undergo radiotherapy area bulk disease feasible . Patients arm meningeal involvement receive ARA-C intrathecally ( IT ) alternate MTX every day 1 week clearing CNS disease 2 IT injection every course chemotherapy thereafter . Patients divergent histology achieve complete response completion arm I II treatment receive interferon alfa 3 time week 1 year . Patients follow 1 month , every 3 month 1 year , every 6 month 1 year , annually 2 year . PROJECTED ACCRUAL : A maximum 136 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis previously untreated intermediategrade immunoblastic lymphoma Tumor score 3 great , define presence 3 follow criterion : Ann Arbor stage III IV disease B symptom ( fever , sweat , weight loss great 10 % ) At least 1 tumor mass great 7 cm mediastinal mass visible plain chest xray Beta2 microglobulin least 3.0 Lactic dehydrogenase least 1.1 time upper limit normal T Bcell lymphoma allow intermediate grade immunoblastic Divergent histology , include bone marrow involvement , allow CNS involvement allow NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 15 59 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dL ( unless elevation due lymphoma ) Renal : Creatinine great 1.5 mg/dL ( unless elevation due lymphoma ) Cardiovascular : LVEF great 50 % echocardiogram age 45 No congestive heart failure , angina , history myocardial infarction , arrhythmia unless clear principal investigator cardiology consultation Pulmonary : No history chronic obstructive restrictive lung disease Pulmonary consultation require smoker patient questionable lung function Other : HIV negative Not pregnant nurse Fertile patient must use effective contraception No prior malignancy poor prognosis ( le 90 % probability survive 5 year ) No geographic , economic , emotional , social condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy Chemotherapy No prior chemotherapy Endocrine therapy No prior endocrine therapy Radiotherapy No prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
</DOC>